Dear Sir, We have read with great interest the article entitled "Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism" by J. Maring et al. which was recently published in the European Journal of Clinical Pharmacology [1] . We would like to comment on the article by referring to our own non-clinical and clinical studies evaluating the relationships between cytidine deaminase (CDA) gene status (either determined on a phenotypic or a genotypic basis) and the pharmacokinetics or clinical outcome of individuals treated with gemcitabine [2] .
Maring et al. studied the impact of the 79A>C polymorphism in the CDA gene on the pharmacokinetics of gemcitabine and its main inactive metabolite 2′,2′-difluorodeoxyuridine (dFdU) in non-small-cell lung cancer (NSCLC) patients. They conclude from this genotype-based study that this polymorphism has little ultimate impact on gemcitabine pharmacokinetics. Of note, in their study, CDA status was never evaluated using a functional test, and no clinical data (e.g., relationships between allelic variants and the incidence of severe toxicities) were made available to further confirm the minor relevance 79A>C polymorphism had on clinical outcome with gemcitabine. However, as fairly underlined by the authors, several experimental or clinical reports have previously evidenced the importance of the 79A>C mutation, both in terms of its impact on CDA activity, or as a biomarker predictive of toxicity/ response with gemcitabine at the bedside [3] [4] [5] . In their paper, Maring et al. list a variety of possible confounding factors explaining this discrepancy, such as epigenetic deregulations, dose levels, sample size or lack of treatment uniformity in the patients they enrolled.
In light of our own expertise on genetic polymorphism affecting CDA and subsequently with patients undergoing gemcitabine-based therapies, we believe that the absence of impact of the 79A>C that Maring et al. have evidenced is not an artifact. In fact, we reached the same conclusion in a pilot study performed in animals as well as in 150 patients (130 adults, 20 children) designed to evaluate whether CDA genetic polymorphism was a culprit in early severe toxicities upon gemcitabine intake [2] . In our study, we proved that CDA deficiency led to marked alterations of the gemcitabine pharmacokinetics profile in animals, with subsequent unrecoverable haematological toxicities. In patients, the 79A>C mutation was screened along with the 208G>A and 435T>C polymorphisms and failed to be correlated with either CDA activity or clinical outcome. Conversely, sorting the same patients on the basis of CDA phenotypic status, rather than on genotypic status, was fully predictive of those experiencing severe drug-induced toxicities, regardless of the dose administered or the associated treatments. In this respect, the recent study by Maring et al. is of interest because it fully supports the hypothesis that the gemcitabine pharmacoge-netics issue should be better addressed using functional tools, rather than with a candidate gene approach. Finally, we would like to emphasize that the apparently negative conclusions of this paper should not deter physicians from moving toward a more personalized medicine with gemcitabine, since the results depend on the tools you use to customize treatment.
